Cummings Keith Lamont Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
8
Insider Sells Sum
$3.68M

Insider Activity of Cummings Keith Lamont

According to the SEC Form 4 filings, Cummings Keith Lamont, being in a position of

  1. Chief Financial Officer at Pliant Therapeutics, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 24002 shares for $30,723,
    over all time since 2020-12-01, has bought 0 shares, and sold 181327 shares for $3.71M.

Biography of Cummings Keith Lamont

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $000
Sells
 $30,7231100

Comparison of Insiders on Amount of Buys and Sells

2026-01-20SalePliant Therapeutics, Inc.
PLRX
Chief Financial Officer
24,002
0.0391%
$1.28$30,723-9.38%
2025-01-17SalePliant Therapeutics, Inc.
PLRX
Chief Financial Officer
20,148
0.0333%
$11.20$225,680-86.57%
2024-07-10SalePliant Therapeutics, Inc.
PLRX
Chief Financial Officer
10,911
0.0198%
$11.56$126,131+2.03%
2024-01-17SalePliant Therapeutics, Inc.
PLRX
Chief Financial Officer
9,781
0.0157%
$17.23$168,527-24.72%
2023-07-17SalePliant Therapeutics, Inc.
PLRX
Chief Financial Officer
19,771
0.0356%
$18.01$356,058-14.41%
2023-03-30SalePliant Therapeutics, Inc.
PLRX
Chief Financial Officer
9,960
0.0178%
$26.52$264,148-35.4%
2023-01-23SalePliant Therapeutics, Inc.
PLRX
Chief Financial Officer
30,000
0.0619%
$35.00$1.05M-39.7%
2022-12-20SalePliant Therapeutics, Inc.
PLRX
Chief Financial Officer
19,286
0.0396%
$19.10$368,409-0.84%
2020-12-01SalePliant Therapeutics, Inc.
PLRX
Chief Financial Officer
37,468
0.1056%
$30.00$1.12M-10.65%
Total: 9
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.